# Charles W M Roberts

List of Publications by Year
in descending order



| 79 | 18,576 | 31976 53 | 71685 76 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 85 | 85 | 85 | 29196 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 2013, 499, 214-218. | 27.8 | 4,761 |
| 2 | Targeting EZH2 in cancer. Nature Medicine, 2016, 22, 128-134. | 30.7 | 1,174 |
| 3 | SWI/SNF nucleosome remodellers and cancer. Nature Reviews Cancer, 2011, 11, 481-492. | 28.4 | 1,035 |
| 4 | Toward understanding and exploiting tumor heterogeneity. Nature Medicine, 2015, 21, 846-853. | 30.7 | 604 |
| 5 | The SWI/SNF complex â€" chromatin and cancer. Nature Reviews Cancer, 2004, 4, 133-142. | 28.4 | 551 |
| 6 | Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation. Cancer Cell, 2010, 18, 316-328. | 16.8 | 531 |
| 7 | Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discovery, 2016, 6, 914-929. | 9.4 | 485 |
| 8 | Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science, 1991, 253, 79-82. | 12.6 | 414 |
| 9 | Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13796-13800. | 7.1 | 384 |
| 10 | Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5564-73. | 7.1 | 355 |
| 11 | ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?. Cancer Discovery, 2013, 3, 35-43. | 9.4 | 347 |
| 12 | A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. Journal of Clinical Investigation, 2012, 122, 2983-2988. | 8.2 | 347 |
| 13 | ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nature Medicine, 2014, 20, 251-254. | 30.7 | 336 |
| 14 | SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nature Medicine, 2015, 21, 1491-1496. | 30.7 | 334 |
| 15 | AP-1 Transcription Factors and the BAF Complex Mediate Signal-Dependent Enhancer Selection. Molecular Cell, 2017, 68, 1067-1082.e12. | 9.7 | 328 |
| 16 | Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3128-3133. | 7.1 | 306 |
| 17 | Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell, 2002, 2, 415-425. | 16.8 | 303 |
| 18 | The SWI/SNF complex in cancer â€" biology, biomarkers and therapy. Nature Reviews Clinical Oncology, 2020, 17, 435-448. | 27.6 | 297 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers. Nature Communications, 2017, 8, 14648. | 12.8 | 274 |
| 20 | SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nature Genetics, 2017, 49, 289-295. | 21.4 | 268 |
| 21 | ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nature Genetics, 2017, 49, 296-302. | 21.4 | 260 |
| 22 | Hox11 controls the genesis of the spleen. Nature, 1994, 368, 747-749. | 27.8 | 254 |
| 23 | Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nature Medicine, 2010, 16, 1429-1433. | 30.7 | 224 |
| 24 | Vulnerabilities of Mutant SWI/SNF Complexes in Cancer. Cancer Cell, 2014, 26, 309-317. | 16.8 | 224 |
| 25 | Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17745-17750. | 7.1 | 198 |
| 26 | On the Key Role of Secondary Lymphoid Organs in Antiviral Immune Responses Studied in Alymphoplastic (aly/aly) and Spleenless (Hox11â^'/â^') Mutant Mice. Journal of Experimental Medicine, 1997, 185, 2157-2170. | 8.5 | 187 |
| 27 | The role of SMARCB1/INI1 in the development of rhabdoid tumors. Cancer Biology and Therapy, 2009, 8, 412-416. | 3.4 | 185 |
| 28 | Atypical teratoid/rhabdoid tumorsâ€"current concepts, advances in biology, and potential future therapies. Neuro-Oncology, 2016, 18, 764-778. | 1.2 | 185 |
| 29 | Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 (BRG1) Mutation. Molecular and Cellular Biology, 2014, 34, 1136-1144. | 2.3 | 176 |
| 30 | Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10165-10170. | 7.1 | 174 |
| 31 | Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors. JAMA Oncology, 2016, 2, 608. | 7.1 | 172 |
| 32 | Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancerâ€"Mechanisms and Potential Therapeutic Insights. Clinical Cancer Research, 2014, 20, 21-27. | 7.0 | 166 |
| 33 | Oncogenesis Caused by Loss of the SNF5 Tumor Suppressor Is Dependent on Activity of BRG1, the ATPase of the SWI/SNF Chromatin Remodeling Complex. Cancer Research, 2009, 69, 8094-8101. | 0.9 | 143 |
| 34 | Linking the SWI/SNF complex to prostate cancer. Nature Genetics, 2013, 45, 1268-1269. | 21.4 | 137 |
| 35 | Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene, 2014, 33, 5295-5302. | 5.9 | 132 |
| 36 | Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15988-15993. | 7.1 | 131 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Metagene projection for cross-platform, cross-species characterization of global transcriptional states. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5959-5964. | 7.1 | 126 |
| 38 | Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genetics, 2014, 207, 365-372. | 0.4 | 119 |
| 39 | BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors. Nature Communications, 2019, 10, 1881. | 12.8 | 117 |
| 40 | CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. Journal of Clinical Investigation, 2017, 128, 446-462. | 8.2 | 117 |
| 41 | Loss of the Epigenetic Tumor Suppressor SNF5 Leads to Cancer without Genomic Instability. Molecular and Cellular Biology, 2008, 28, 6223-6233. | 2.3 | 116 |
| 42 | Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature, 2017, 542, 362-366. | 27.8 | 105 |
| 43 | A first-generation pediatric cancer dependency map. Nature Genetics, 2021, 53, 529-538. | 21.4 | 76 |
| 44 | Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatric Blood and Cancer, 2012, 59, 1155-1157. | 1.5 | 75 |
| 45 | Activation of Î²-catenin/TCF targets following loss of the tumor suppressor SNF5. Oncogene, 2014, 33, 933-938. | 5.9 | 72 |
| 46 | SWI/SNF Deficiency Results in Aberrant Chromatin Organization, Mitotic Failure, and Diminished Proliferative Capacity. Molecular Biology of the Cell, 2009, 20, 3192-3199. | 2.1 | 70 |
| 47 | PGBD5 promotes site-specific oncogenic mutations in human tumors. Nature Genetics, 2017, 49, 1005-1014. | 21.4 | 69 |
| 48 | Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. Cancer Cell, 2019, 35, 95-110.e8. | 16.8 | 65 |
| 49 | cBAF complex components and MYC cooperate early in CD8+ T cell fate. Nature, 2022, 607, 135-141. | 27.8 | 65 |
| 50 | p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell, 2019, 35, 204-220.e9. | 16.8 | 62 |
| 51 | TCR-dependent transformation of mature memory phenotype T cells in mice. Journal of Clinical Investigation, 2011, 121, 3834-3845. | 8.2 | 62 |
| 52 | Epigenetics and Cancer: Altered Chromatin Remodeling via Snf5 Loss Leads to Aberrant Cell Cycle Regulation. Cell Cycle, 2006, 5, 621-624. | 2.6 | 58 |
| 53 | The t(10;14)(q24;q11) of T-cell acute lymphoblastic leukemia juxtaposes the delta T-cell receptor with TCL3, a conserved and activated locus at 10q24.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 3161-3165. | 7.1 | 57 |
| 54 | The SWI/SNF tumor suppressor complex. Nucleus, 2013, 4, 374-378. | 2.2 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Renal Medullary Carcinoma: Establishing Standards in Practice. Journal of Oncology Practice, 2017, 13, 414-421. | 2.5 | 52 |
| 56 | Fibroblast Growth Factor Receptors as Novel Therapeutic Targets in SNF5-Deleted Malignant Rhabdoid Tumors. PLoS ONE, 2013, 8, e77652. | 2.5 | 47 |
| 57 | TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Reports, 2018, 25, 1255-1267.e5. | 6.4 | 46 |
| 58 | Integrated genetic and pharmacologic interrogation of rare cancers. Nature Communications, 2016, 7, 11987. | 12.8 | 45 |
| 59 | Epigenetics and cancer without genomic instability. Cell Cycle, 2009, 8, 23-26. | 2.6 | 43 |
| 60 | MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors. Cancer Research, 2019, 79, 2404-2414. | 0.9 | 43 |
| 61 | Molecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor. Oncotarget, 2016, 7, 1732-1740. | 1.8 | 42 |
| 62 | Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. Cell Cycle, 2012, 11, 1956-1965. | 2.6 | 25 |
| 63 | Rhabdoid Tumors: An Initial Clue to the Role of Chromatin Remodeling in Cancer. Brain Pathology, 2013, 23, 200-205. | 4.1 | 25 |
| 64 | Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Reports, 2019, 28, 2331-2344.e8. | 6.4 | 24 |
| 65 | Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5<sup>+/â^'</sup>;p53<sup>+/â^'</sup> mice. Molecular Carcinogenesis, 2009, 48, 1139-1148. | 2.7 | 23 |
| 66 | Functionally distinct patterns of nucleosome remodeling at enhancers in glucocorticoid-treated acute lymphoblastic leukemia. Epigenetics and Chromatin, 2015, 8, 53. | 3.9 | 22 |
| 67 | CHD7 in Charge of Neurogenesis. Cell Stem Cell, 2013, 13, 1-2. | 11.1 | 21 |
| 68 | Tumor-Specific Cooperation of Retinoblastoma Protein Family and Snf5 Inactivation. Cancer Research, 2007, 67, 3002-3009. | 0.9 | 18 |
| 69 | NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition. Molecular Cell, 2022, 82, 2472-2489.e8. | 9.7 | 18 |
| 70 | CARMA: CARM1 Methylation of SWI/SNF in Breast Cancer. Cancer Cell, 2014, 25, 3-4. | 16.8 | 14 |
| 71 | Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. Clinical Cancer Research, 2020, 26, 4995-5006. | 7.0 | 14 |
| 72 | Partitioning of Chemotherapeutics into Nuclear Condensatesâ€"Opening the Door to New Approaches for Drug Development. Molecular Cell, 2020, 79, 544-545. | 9.7 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Abstract A41: Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. , 2014, , . | | 4 |
| 74 | Genetic causes of familial risk in rhabdoid tumors. Pediatric Blood and Cancer, 2006, 47, 235-237. | 1.5 | 3 |
| 75 | Establishment and characterization of MRT cell lines from genetically engineered mouse models and the influence of genetic background on their development. International Journal of Cancer, 2013, 132, 2767-2777. | 5.1 | 3 |
| 76 | Abstract LB-286: ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. , 2017, , . | | 1 |
| 77 | Cancer-fighting Smurf. Nature Medicine, 2012, 18, 204-205. | 30.7 | 0 |
| 78 | High Frequency of Ovarian Cyst Development in Vhl;Snf5 Mice. American Journal of Pathology, 2018, 188, 1510-1516. | 3.8 | 0 |
| 79 | Abstract SY07-01: The SWI/SNF chromatin remodeling complex is frequently mutated in cancer: Mechanisms and potential therapeutic insights.. , 2013, , . | | 0 |